Listen and follow our podcasts on:

Bayer.

Oncology Brothers Drs Rahul and Rohit Gosain facilitate a podcast discussion between medical oncologist Prof Tanios Bekaii-Saab and Deneen Richmond, a patient advocate and healthcare executive who has herself experienced rectal cancer.

 

Together, they look at how to manage the needs of different patient populations with colorectal cancer, focusing on age, ethnicity, socioeconomic status, and access to healthcare.  The experts share their own experiences of practising oncology and surviving cancer.

 

The speakers discuss a range of topics, including:

  • Education and awareness needs of different ethnic groups such as African Americans, Hispanics and Asian Americans and the importance of building trust within these populations
  • The unique needs of younger patients and the challenges they face, such as managing work, caring for family members and children
  • The importance of encouraging screening leading to early diagnosis in these patient groups

 

Clinical takeaways

  • Understanding the diverse needs of different patient populations with colorectal cancer is crucial for delivering effective care.
  • Disparities in access to healthcare services and quality of care exist among different patient populations.
  • Healthcare inequities can be addressed by promoting education and awareness and ensuring culturally sensitive care delivery for all patient populations.
  • Collaboration through patient and caregiver advocates and trusted members of the community can improve overall healthcare quality.

This programme is available as a CME accredited e-learning.

Understanding the needs of different patient populations in colorectal cancer: Educational objectives

  • To help healthcare professionals understand the needs of different ethnicities and other specific patient groups in colorectal cancer and how to address them

Tanios Bekaii-Saab, MD is a Professor of Medicine at the Mayo Clinic College of Medicine and Science. He is the Chair for Hematology and Medical Oncology for the Division of Hematology/Oncology at the Mayo Clinic in Phoenix, Arizona, USA. He is the leader of the Gastrointestinal Cancer for the Enterprise-wide Mayo Clinic Cancer Center Dr. Bekaii-Saab is currently the co-leader of the Hepatobiliary Cancer Sub-Committee of the Alliance for Clinical Trials in Oncology and the Co-Chair for the National Cancer Institute’s Hepatobiliary Task Force.

 

Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana, USA. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts, USA.


Dr. Bekaii-Saab served as a reviewer for many high impact journals and sits on the editorial board of the prestigious Journal of the National Cancer Institute. Dr. Bekaii-Saab has authored or co-authored more than 500 peer reviewed publications, abstracts, and book chapters, including papers in such journals as New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.

Prof. Tanios Bekaii-Saab has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research Funding (to institution): Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS. Consulting (to institution): Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA and Merck. Consulting (to self): Stemline, AbbVie, Blueprint Medicines , Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine and Sanofi. Glaxo SmithKline , Xilio. IDMC/DSMB: The Valley Hospital, Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan and 1Globe.  Scientific Advisory Board: Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma. Royalties: Uptodate. Inventions/Patents: WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene, WO/2019/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion

In February 2023, Deneen Richmond’s life was forever changed when she was diagnosed with Stage 3 rectal cancer. After a year of treatment including chemotherapy, chem-radiation and surgery, Ms. Richmond is proud to shout from the rooftops that she has no evidence of disease. Deneen has shared her personal journey in many forums, and is dedicated to being a patient advocate, erasing the stigma and educating others about colorectal cancer. Deneen is also passionate about improving the health of our communities, promoting health equity and eradicating health disparities.


Deneen has more than 30 years of healthcare leadership experience and currently is the president of a 200+ bed community hospital in Maryland. She has a bachelor’s degree in nursing from the University of the District of Columbia and a master’s degree in health care administration from The George Washington University. She is the author of two chapters in The Healthcare Quality Book, fifth edition, published in 2023 – Health Equity and Diversity; and Population Health. Deneen serves as adjunct faculty at the George Washington University, Milken School of Public Health in the executive masters in health administration programme. She has received numerous professional awards and recognitions.


Deneen uniquely brings the perspective as a patient advocate, a registered nurse and an accomplished healthcare executive. Her most important experience comes from being a patient as a person diagnosed with cancer.

Drs. Rohit Gosain and Rahul Gosain, the Oncology Brothers, are board certified in internal medicine, hematology, and oncology. They work in the community setting as generalists, and their mission is to bridge the gap between the community and academia by providing key insights and succinct conference updates, discussing practice-changing data, and reiterating the standard of care.

Oncology Brothers (Moderators) has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr. Rahul Gosain

Consultancy / advisory: AstraZeneca, Gilead, Janssen Oncology

Honorarium: MJH Lifesciences, SignifyMD/Oncology News Central, COR2ED, Integrity CE

 

Dr. Rohit Gosain

Consultancy / advisory: Eisai

Honorarium: MJH Lifesciences, SignifyMD/Oncology News Central, COR2ED, Integrity CE

Listen and follow our podcasts on:

Bayer.

Oncology Brothers Drs Rahul and Rohit Gosain facilitate a podcast discussion between medical oncologist Prof Tanios Bekaii-Saab and Deneen Richmond, a patient advocate and healthcare executive who has herself experienced rectal cancer.

 

Together, they look at how to manage the needs of different patient populations with colorectal cancer, focusing on age, ethnicity, socioeconomic status, and access to healthcare.  The experts share their own experiences of practising oncology and surviving cancer.

 

The speakers discuss a range of topics, including:

  • Education and awareness needs of different ethnic groups such as African Americans, Hispanics and Asian Americans and the importance of building trust within these populations
  • The unique needs of younger patients and the challenges they face, such as managing work, caring for family members and children
  • The importance of encouraging screening leading to early diagnosis in these patient groups

 

Clinical takeaways

  • Understanding the diverse needs of different patient populations with colorectal cancer is crucial for delivering effective care.
  • Disparities in access to healthcare services and quality of care exist among different patient populations.
  • Healthcare inequities can be addressed by promoting education and awareness and ensuring culturally sensitive care delivery for all patient populations.
  • Collaboration through patient and caregiver advocates and trusted members of the community can improve overall healthcare quality.

This programme is available as a CME accredited e-learning.

Understanding the needs of different patient populations in colorectal cancer: Educational objectives

  • To help healthcare professionals understand the needs of different ethnicities and other specific patient groups in colorectal cancer and how to address them

Tanios Bekaii-Saab, MD is a Professor of Medicine at the Mayo Clinic College of Medicine and Science. He is the Chair for Hematology and Medical Oncology for the Division of Hematology/Oncology at the Mayo Clinic in Phoenix, Arizona, USA. He is the leader of the Gastrointestinal Cancer for the Enterprise-wide Mayo Clinic Cancer Center Dr. Bekaii-Saab is currently the co-leader of the Hepatobiliary Cancer Sub-Committee of the Alliance for Clinical Trials in Oncology and the Co-Chair for the National Cancer Institute’s Hepatobiliary Task Force.

 

Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana, USA. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts, USA.


Dr. Bekaii-Saab served as a reviewer for many high impact journals and sits on the editorial board of the prestigious Journal of the National Cancer Institute. Dr. Bekaii-Saab has authored or co-authored more than 500 peer reviewed publications, abstracts, and book chapters, including papers in such journals as New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.

Prof. Tanios Bekaii-Saab has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research Funding (to institution): Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS. Consulting (to institution): Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA and Merck. Consulting (to self): Stemline, AbbVie, Blueprint Medicines , Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine and Sanofi. Glaxo SmithKline , Xilio. IDMC/DSMB: The Valley Hospital, Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan and 1Globe.  Scientific Advisory Board: Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma. Royalties: Uptodate. Inventions/Patents: WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene, WO/2019/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion

In February 2023, Deneen Richmond’s life was forever changed when she was diagnosed with Stage 3 rectal cancer. After a year of treatment including chemotherapy, chem-radiation and surgery, Ms. Richmond is proud to shout from the rooftops that she has no evidence of disease. Deneen has shared her personal journey in many forums, and is dedicated to being a patient advocate, erasing the stigma and educating others about colorectal cancer. Deneen is also passionate about improving the health of our communities, promoting health equity and eradicating health disparities.


Deneen has more than 30 years of healthcare leadership experience and currently is the president of a 200+ bed community hospital in Maryland. She has a bachelor’s degree in nursing from the University of the District of Columbia and a master’s degree in health care administration from The George Washington University. She is the author of two chapters in The Healthcare Quality Book, fifth edition, published in 2023 – Health Equity and Diversity; and Population Health. Deneen serves as adjunct faculty at the George Washington University, Milken School of Public Health in the executive masters in health administration programme. She has received numerous professional awards and recognitions.


Deneen uniquely brings the perspective as a patient advocate, a registered nurse and an accomplished healthcare executive. Her most important experience comes from being a patient as a person diagnosed with cancer.

Drs. Rohit Gosain and Rahul Gosain, the Oncology Brothers, are board certified in internal medicine, hematology, and oncology. They work in the community setting as generalists, and their mission is to bridge the gap between the community and academia by providing key insights and succinct conference updates, discussing practice-changing data, and reiterating the standard of care.

Oncology Brothers (Moderators) has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr. Rahul Gosain

Consultancy / advisory: AstraZeneca, Gilead, Janssen Oncology

Honorarium: MJH Lifesciences, SignifyMD/Oncology News Central, COR2ED, Integrity CE

 

Dr. Rohit Gosain

Consultancy / advisory: Eisai

Honorarium: MJH Lifesciences, SignifyMD/Oncology News Central, COR2ED, Integrity CE

Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ASCO 2025

Coming Soon: Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Dr Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • clock MIN
  • calendar Jun 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
conference-update Conference update
Oncology 
Highlights from ASCO 2025: BRAF-mutant colorectal cancer (CRC)

Expert opinion on the latest practice-changing data

Experts
Prof. Dominik Modest, Prof. Sara Lonardi
Endorsed by
DiCE ICAN international cancer advocacy network BRAF Bombers
Biomarker Collaborative
  • clock 5 MIN
  • calendar Jun 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.